Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 Unmet Need: Treatment Tolerability 23
6.2.2 Unmet Need: Efficacy 23
6.2.3 Unmet Need: Disease Awareness 24
6.2.4 Unmet Need: Treatment Cost 25
6.2.5 Unmet Need: Shorter Treatment Duration 25
6.2.6 Unmet Need: Simplified Treatment Regimens 26
6.3 Unmet Needs Gap Analysis 26
6.4 Opportunities 27
6.4.1 Opportunity: Pan-genotypic HCV Regimen 27
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 27
6.4.3 Opportunity: Involvement of Immune System 28
7 Pipeline Assessment 29
7.1 Overview 29
7.2 Promising Drugs in Clinical Development 30
8 Sofosbuvir and Sofosbuvir/Ledipasvir 32
8.1 Overview 32
8.2 Efficacy 35
8.3 Safety 37
8.4 Dosing and Formulation 37
8.5 Potential Clinical Positioning 38
8.6 Potential Commercial Positioning 39
8.7 Pricing and Reimbursement 39
8.8 SWOT Analysis 40
8.9 Forecast 41
9 Appendix 44
9.1 Bibliography 44
9.2 Abbreviations 47
9.3 Methodology 48
9.4 Forecasting Methodology 48
9.4.1 Percent Drug-Treated Patients 48
9.4.2 Patient Warehousing 49
9.4.3 General Pricing Assumptions 49
9.4.4 Pricing of Pipeline Agents 50
9.5 Physicians and Specialists Included in this Study 51
9.6 Survey of Prescribing Physicians 53
9.7 About the Authors 54
9.7.1 Author 54
9.7.2 Global Head of Healthcare 54
9.8 About GlobalData 55
9.9 Contact Us 55
9.10 Disclaimer 55